keyword
https://read.qxmd.com/read/38485445/what-makes-a-cyanobacterial-bloom-disappear-a-review-of-the-abiotic-and-biotic-cyanobacterial-bloom-loss-factors
#21
REVIEW
Ted D Harris, Kaitlin L Reinl, Marzi Azarderakhsh, Stella A Berger, Manuel Castro Berman, Mina Bizic, Ruchi Bhattacharya, Sarah H Burnet, Jacob A Cianci-Gaskill, Lisette N de Senerpont Domis, Inge Elfferich, K Ali Ger, Hans-Peter F Grossart, Bas W Ibelings, Danny Ionescu, Zohreh Mazaheri Kouhanestani, Jonas Mauch, Yvonne R McElarney, Veronica Nava, Rebecca L North, Igor Ogashawara, Ma Cristina A Paule-Mercado, Sara Soria-Píriz, Xinyu Sun, Jessica V Trout-Haney, Gesa A Weyhenmeyer, Kiyoko Yokota, Qing Zhan
Cyanobacterial blooms present substantial challenges to managers and threaten ecological and public health. Although the majority of cyanobacterial bloom research and management focuses on factors that control bloom initiation, duration, toxicity, and geographical extent, relatively little research focuses on the role of loss processes in blooms and how these processes are regulated. Here, we define a loss process in terms of population dynamics as any process that removes cells from a population, thereby decelerating or reducing the development and extent of blooms...
March 2024: Harmful Algae
https://read.qxmd.com/read/38485443/mechanisms-of-harmful-effects-of-microcystis-aeruginosa-on-a-brackish-water-organism-moina-mongolica-based-on-physiological-and-transcriptomic-responses
#22
JOURNAL ARTICLE
Hongtao Liu, Hao Xing, Zhangyi Xia, Tingting Wu, Jinlin Liu, Aiqin Li, Fangling Bi, Yuqing Sun, Jianheng Zhang, Peimin He
To investigate the detrimental impacts of cyanobacterial bloom, specifically Microcystis aeruginosa, on brackish water ecosystems, the study used Moina mongolica, a cladoceran species, as the test organism. In a chronic toxicology experiment, the survival and reproductive rates of M. mongolica were assessed under M. aeruginosa stress. It was observed that the survival rate of M. mongolica fed with M. aeruginosa significantly decreased with time and their reproduction rate dropped to zero, while the control group remained maintained stable and normal reproduction...
March 2024: Harmful Algae
https://read.qxmd.com/read/38485289/btn1a1-is-a-novel-immune-checkpoint-mutually-exclusive-to-pd-l1
#23
JOURNAL ARTICLE
Young-Seung Kim, Seung-Hoon Lee, Andrew H Park, Chunai Wu, Bong-Ki Hong, Hyunjin Jung, Steven H Lin, Stephen S Yoo
BACKGROUND: While Programmed cell death protein 1 (PD-1)/programmed cell death-ligand 1 (PD-L1) blockade is a potent antitumor treatment strategy, it is effective in only limited subsets of patients with cancer, emphasizing the need for the identification of additional immune checkpoints. Butyrophilin 1A1 (BTN1A1) has been reported to exhibit potential immunoregulatory activity, but its ability to function as an immune checkpoint remains to be systematically assessed, and the mechanisms underlying such activity have yet to be characterized...
March 14, 2024: Journal for Immunotherapy of Cancer
https://read.qxmd.com/read/38485188/efficacy-safety-and-biomarker-analyses-of-bintrafusp-alfa-a-bifunctional-fusion-protein-targeting-tgf-%C3%AE-and-pd-l1-in-patients-with-advanced-non-small-cell-lung-cancer
#24
JOURNAL ARTICLE
Arun Rajan, Houssein Abdul Sater, Osama Rahma, Richy Agajanian, Wiem Lassoued, Jennifer L Marté, Yo-Ting Tsai, Renee N Donahue, Elizabeth Lamping, Shania Bailey, Andrew Weisman, Beatriz Walter-Rodriguez, Rena Ito, Yulia Vugmeyster, Masashi Sato, Andreas Machl, Jeffrey Schlom, James L Gulley
BACKGROUND: Bintrafusp alfa, a first-in-class bifunctional fusion protein targeting transforming growth factor-β (TGF-β) and programmed cell death ligand 1, has demonstrated encouraging efficacy as second-line treatment in patients with non-small cell lung cancer (NSCLC) in a dose expansion cohort of the phase 1, open-label clinical trial (NCT02517398). Here, we report the safety, efficacy, and biomarker analysis of bintrafusp alfa in a second expansion cohort of the same trial (biomarker cohort)...
March 13, 2024: Journal for Immunotherapy of Cancer
https://read.qxmd.com/read/38485184/phase-ii-study-of-nivolumab-in-patients-with-genetic-alterations-in-dna-damage-repair-and-response-who-progressed-after-standard-treatment-for-metastatic-solid-cancers-km-06
#25
JOURNAL ARTICLE
Ju Won Kim, Hyo Jin Lee, Ji Yoon Lee, Sook Ryun Park, Yu Jung Kim, In Gyu Hwang, Woo Kyun Bae, Jae Ho Byun, Jung Sun Kim, Eun Joo Kang, Jeeyun Lee, Sang Joon Shin, Won Jin Chang, Eun-Ok Kim, Jason K Sa, Kyong Hwa Park
BACKGROUND: Immune-modulating antibodies targeting programmed cell death protein 1/programmed death-ligand 1 (PD-1/PD-L1) have demonstrated promising antitumor efficacy in various types of cancers, especially highly mutated ones. Genetic alterations in DNA damage response and repair (DDR) genes can lead to genetic instability, often accompanied by a high tumor mutation burden (TMB). However, few studies have validated the aberration of DDR genes as a predictive biomarker for response to immune-modulating antibodies...
March 13, 2024: Journal for Immunotherapy of Cancer
https://read.qxmd.com/read/38484645/acrylonitrile-derivatives-in-vitro-activity-and-mechanism-of-cell-death-induction-against-trypanosoma-cruzi-and-leishmania-amazonensis
#26
JOURNAL ARTICLE
Carlos J Bethencourt-Estrella, Samuel Delgado-Hernández, Atteneri López-Arencibia, Desirée San Nicolás-Hernández, Lizbeth Salazar-Villatoro, Maritza Omaña-Molina, David Tejedor, Fernando García-Tellado, Jacob Lorenzo-Morales, José E Piñero
Leishmaniasis and Chagas disease are parasitic infections that affect millions of people worldwide, producing thousands of deaths per year. The current treatments against these pathologies are not totally effective and produce some side effects in the patients. Acrylonitrile derivatives are a group of compounds that have shown activity against these two diseases. In this work, four novels synthetic acrylonitriles were evaluated against the intracellular form and extracellular forms of L. amazonensis and T. cruzi...
March 6, 2024: International Journal for Parasitology, Drugs and Drug Resistance
https://read.qxmd.com/read/38484644/il-13-facilitates-ferroptotic-death-in-asthmatic-epithelial-cells-via-socs1-mediated-ubiquitinated-degradation-of-slc7a11
#27
JOURNAL ARTICLE
Manli Miao, Min Pan, Xu Chen, Jiapan Shen, Ling Zhang, Xiaoxia Feng, Mengting Chen, Guofeng Cui, Huaiyuan Zong, Wen Zhang, Shuang Chang, Fangzhou Xu, Zixi Wang, Dapeng Li, Weiwei Liu, Zhao Ding, Shengquan Zhang, Biao Chen, Xiaojun Zha, Xiaoyun Fan
Th2-high asthma is characterized by elevated levels of type 2 cytokines, such as interleukin 13 (IL-13), and its prevalence has been increasing worldwide. Ferroptosis, a recently discovered type of programmed cell death, is involved in the pathological process of Th2-high asthma; however, the underlying mechanisms remain incompletely understood. In this study, we demonstrated that the serum level of malondialdehyde (MDA), an index of lipid peroxidation, positively correlated with IL-13 level and negatively correlated with the predicted forced expiratory volume in 1 s (FEV1%) in asthmatics...
March 8, 2024: Redox Biology
https://read.qxmd.com/read/38484186/a-bioinspired-immunostimulatory-system-for-inducing-powerful-antitumor-immune-function-by-directly-causing-plasma-membrane-rupture
#28
JOURNAL ARTICLE
Xiaoqu Hu, Hao Yin, Danli Xie, Tanzhou Chen, Yida Li, Hanqian Zeng, Mingdong Lu, Qinyang Wang
The Gasdermin protein is a membrane disruptor that can mediate immunogenic pyroptosis and elicit anti-tumor immune function. However, cancer cells downregulate Gasdermin and develop membrane repair mechanisms to resist pyroptosis. Therefore, an artificial membrane disruptor (AMD) that can directly mediate membrane rupture in pyroptosis-deficient cells and induce antitumor immune responses in a controllable manner will be valuable in preclinical and clinical research. A micron-scale Ce6-based AMD that can directly induce plasma membrane rupture (PMR) in gasdermin-deficient tumor cells is established...
March 14, 2024: Advanced Science (Weinheim, Baden-Wurttemberg, Germany)
https://read.qxmd.com/read/38483700/pyruvate-kinase-m2-nuclear-translocation-regulate-ferroptosis-associated-acute-lung-injury-in-cytokine-storm
#29
JOURNAL ARTICLE
Haiting Wang, Chenyu Fan, Xuelian Chen, Wei Zhou, Li Guo, Feng Zhao, Shuang Ye, Shuangjun He, Yi Chen
Cytokine storm (CS) is linked with macrophage dysfunction and acute lung injury (ALI), which can lead to patient mortality. Glycolysis is preferentially exploited by the pro-inflammatory macrophages, in which pyruvate kinase M2 (PKM2) is a critical enzyme. The mechanism underlying the link between CS and ALI involves cell death, with the recently discovered programmed cell death known as ferroptosis being involved. However, the relationship between the glycolysis and ferroptosis in the context of CS-related ALI remains unclear...
March 14, 2024: Inflammation
https://read.qxmd.com/read/38482921/cyclin-dependent-kinase-inhibitors-enhance-programmed-cell-death-protein-1-immune-checkpoint-blockade-efficacy-in-triple-negative-breast-cancer-by-affecting-the-immune-microenvironment
#30
JOURNAL ARTICLE
Jiayi Wu, Wei Wang, Lu Gao, Xiying Shao, Xiaojia Wang
BACKGROUND: Clinical studies on programmed death-ligand 1 (PD-L1) immune checkpoint inhibitors for treating triple-negative breast cancer (TNBC) have shown unsatisfactory efficacy due to low tumor-infiltrating lymphocyte (TIL) levels. Inhibitors targeting cyclin-dependent kinase (CDK) proteins can affect the immune microenvironment, increase TIL levels, and promote antitumor immunity, thus providing a new direction for TNBC treatment strategies. METHODS: The authors tested three CDK inhibitors on the TNBC cell lines MDA-MB-231 and 4T1 and validated their antitumor effects and impact on the immune microenvironment using multiple detection methods...
March 14, 2024: Cancer
https://read.qxmd.com/read/38482619/investigating-the-effects-of-dorema-hyrcanum-root-extracts-on-selective-induction-of-programmed-cell-death-in-glioblastoma-ovarian-cancer-and-breast-cancer-cell-lines
#31
JOURNAL ARTICLE
Mahsa Hatami, Shamim Sahranavard, Fereshteh Bagheri, Zahra Shahsavari, Siamak Salami
BACKGROUND: Despite remarkable advances, cancer has remained the second cause of death, which shows that more potent novel compounds should be found. Ethnobotanical compounds have a long history of treating diseases, and several approved chemotherapeutic compounds were isolated from plants. OBJECTIVE: The research aimed to evaluate the cytotoxic effects of Dorema hyrcanum root extract on ovarian, breast, and glioblastoma cells while examining its selectivity towards normal cells...
March 12, 2024: Anti-cancer Agents in Medicinal Chemistry
https://read.qxmd.com/read/38482519/co-delivery-of-aceclofenac-and-methotrexate-nanoparticles-presents-an-effective-treatment-for-rheumatoid-arthritis
#32
JOURNAL ARTICLE
Sushmita Negi, Nikunj Tandel, Neeraj K Garg, Prakriti Sharma, Rajinder Kumar, Praveen Sharma, Reetesh Kumar, Sheetal Saini, Aman Sharma, Rajeev K Tyagi
BACKGROUND: Rheumatoid arthritis (RA) is a common acute inflammatory autoimmune connective tissue arthropathy. The genetic studies, tissue analyses, experimental animal models, and clinical investigations have confirmed that stromal tissue damage and pathology driven by RA mounts the chronic inflammation and dysregulated immune events. METHODS: We developed methotrexate (MTX)-loaded lipid-polymer hybrid nanoparticles (MTX-LPHNPs) and aceclofenac (ACE)-loaded nanostructured lipid carriers (ACE-NLCs) for the efficient co-delivery of MTX and ACE via intravenous and transdermal routes, respectively...
2024: International Journal of Nanomedicine
https://read.qxmd.com/read/38482433/a-real-world-evaluation-of-tislelizumab-in-patients-with-head-and-neck-cancer
#33
JOURNAL ARTICLE
Baomin Zheng, Zhou Huang, Weixin Liu, Dan Zhao, Xiaolong Xu, Shaowen Xiao, Yan Sun, Weihu Wang
BACKGROUND: Various studies support the use of programmed cell death protein 1 (PD-1) blockades, also known as immune checkpoint inhibitors (ICIs), to treat head and neck cancer (HNC). Tislelizumab is a humanised immunoglobulin G4 (IgG4) monoclonal antibody with a high affinity and specificity for PD-1. However, the "real-world" clinical evidence of tislelizumab for HNC is limited. METHODS: In this study, the medical records of 39 patients with head and neck squamous cell carcinoma (HNSCC) or nasopharyngeal carcinoma (NPC) who received tislelizumab between January 2021 and March 2022 were reviewed retrospectively...
February 29, 2024: Translational Cancer Research
https://read.qxmd.com/read/38482415/toripalimab-plus-lenalidomide-for-central-nervous-system-recurrence-in-refractory-cd5-diffuse-large-b-cell-lymphoma-with-myd88-and-cd79b-comutation-a-case-report
#34
Xi Chen, Zhihan Zhang, Junbao Zhang, Qiuxiao Yu, Junjing Qiu, Yajie Xiao, Binbin Chen, Ping Xu
BACKGROUND: CD5-positive (CD5+ ) non-germinal center B-cell-like diffuse large B-cell lymphoma (non-GCB DLBCL) is heterogeneous with a poor prognosis. For refractory DLBCL, the median overall survival was only 6.3 months. Therefore, there is a need for approaches to elongate the survival in this subgroup of relapsed DLBCL patients. CASE DESCRIPTION: Here, we present a rare case of a 72-year-old patient with stage IV CD5+ non-GCB DLBCL with myeloid differentiation primary response 88 ( MYD88 ) and cluster of differentiation 79B ( CD79B ) comutations...
February 29, 2024: Translational Cancer Research
https://read.qxmd.com/read/38482411/pd-1-induced-encephalopathy-a-report-of-2-cases-on-neurological-toxicities-with-immune-checkpoint-inhibitors
#35
Xingrui Chen, Minting Ye, Ruyu Ai, Changguo Shan, Minyao Lai, Weiping Hong, Yanying Yang, Hui Wang, Juan Li, Junjie Zhen, Jiangfen Zhou, Qingjun Hu, Shaoqun Li, Antonio Rossi, Toyoaki Hida, Rafael Rosell, Shuisheng Zhong, Linbo Cai
BACKGROUND: Immune-related adverse effects (irAEs) often occur during immune checkpoint inhibitor (ICI) therapy. In the nervous system, the incidence of irAEs ranges from 0.1-12%, with 80% occurring within the first 4 months of ICI application. For complications of the nervous system, adequate diagnosis is made by signs, symptoms, imaging and cerebrospinal fluid. If severe irAEs occur, ICIs should be discontinued and patients should be treated with high-dose glucocorticoids, immunoglobulins, or immunosorbent therapy with systemic support...
February 29, 2024: Translational Cancer Research
https://read.qxmd.com/read/38482245/regorafenib-combined-with-a-pd-1-inhibitor-in-the-second-line-setting-for-unresectable-hepatocellular-carcinoma-in-real-world-practice
#36
JOURNAL ARTICLE
Huaqiang Bi, Jun Pei, Kuansheng Ma, Yanling Zhang, Giuseppe Aprile, Dimitrios Moris, Nahum Méndez-Sánchez, Hrishikesh Samant, Ximin Sun, Feng Xia
BACKGROUND: Most advanced hepatocellular carcinoma (HCC) cases administered molecular targeted agents and/or anti-programmed cell death-1 (PD-1) inhibitors have no response or develop resistance. Moreover, second-line therapies still cannot provide beneficial clinical outcomes. A pilot study assessing combined regorafenib and PD-1 inhibitor as second-line treatment of advanced HCC reported promising effectiveness. METHODS: The current single-center, retrospective, real-world study was carried out between January 2019 and July 2021...
February 29, 2024: Journal of Gastrointestinal Oncology
https://read.qxmd.com/read/38482227/pd-1-inhibition-combined-with-intensity-modulated-radiotherapy-to-better-serve-patients-with-retroperitoneal-lymph-node-metastases-from-gastrointestinal-cancer
#37
JOURNAL ARTICLE
Yunyun Lu, Zhengxuying Fang, Linglong Tao, Michael D Chuong, Yi Lu
BACKGROUND: Gastrointestinal (GI) cancer is the most frequent kind of cancer to involve the retroperitoneal lymph nodes (RPLNs). Radiotherapy (RT) is common treatment of RPLN metastases in patients with GI cancer, while RT is local. Meanwhile, most patients have extra-retroperitoneal metastases. Immunotherapy plus RT have showed effective in advanced non-small cell lung cancer. However, whether the combination therapy is effective on GI cancer with RPLN metastases. In our study, we would estimate the effect of programmed death-1 (PD-1) inhibition in association with intensity modulated radiation therapy (IMRT)...
February 29, 2024: Journal of Gastrointestinal Oncology
https://read.qxmd.com/read/38482217/camrelizumab-combined-with-apatinib-for-unresectable-metastatic-esophageal-squamous-cell-carcinoma-a-single-center-single-arm-prospective-study
#38
JOURNAL ARTICLE
Yanli Qu, Abulimiti Munire, Ning Zhou, Keyoumu Saifuding, Jilisihan Bulibu, Wei Wang, Xushan Tang, Na Li, Junjie Li, Peihong Wang, Yong Tang
BACKGROUND: The prognosis for esophageal cancer (EC), a common malignant tumor, is poor. The new oral small-molecule tyrosine kinase inhibitor apatinib has shown an excellent therapeutic effect on treating EC. Camrelizumab is a humanized programmed death 1 (PD-1) inhibitor with high affinity. Immune checkpoint inhibitors combined with chemotherapy have become the standard first-line treatment for advanced EC. The new combination strategy of anti-angiogenic therapy combined with immunotherapy has great application prospects in the treatment of tumors...
February 29, 2024: Journal of Gastrointestinal Oncology
https://read.qxmd.com/read/38482205/immunotherapy-associated-cardiovascular-toxicities-insights-from-preclinical-and-clinical-studies
#39
REVIEW
Youqian Kong, Xiaoyu Wang, Rui Qie
Immune checkpoint inhibitors (ICIs) have become a widely accepted and effective treatment for various types of solid tumors. Recent studies suggest that cardiovascular immune-related adverse events (irAEs) specifically have an incidence rate ranging from 1.14% to more than 5%. Myocarditis is the most common observed cardiovascular irAE. Others include arrhythmias, pericardial diseases, vasculitis, and a condition resembling takotsubo cardiomyopathy. Programmed cell death-1 (PD-1)/programmed cell death ligand-1 (PD-L1) pathway, cytotoxic T-lymphocyte antigen-4 (CTLA-4) pathway, and the recently discovered lymphocyte-activation gene 3 (LAG-3) pathway, play a critical role in boosting the body's natural immune response against cancer cells...
2024: Frontiers in Oncology
https://read.qxmd.com/read/38481961/distinguishing-two-distinct-types-of-salivary-extracellular-vesicles-a-potential-tool-for-understanding-their-pathophysiological-roles
#40
JOURNAL ARTICLE
Yuko Ogawa, Yuri Miura, Mamoru Ikemoto, Atsushi Ohnishi, Yoshikuni Goto, Kazuma Aoki, Yuki Motokurumada, Yoshihiro Akimoto, Tamao Endo, Masafumi Tsujimoto, Ryohei Yanoshita
Extracellular vesicles (EVs), which are found in almost all cells and human body fluids, are currently being studied as a source of pathophysiological information. Previously, we demonstrated that at least two types of EVs can be isolated from human whole saliva (WS) using enzymatic activity of dipeptidyl peptidase IV (DPP IV) as a marker for differentiating the EV subsets. In the present study, EV fractions, termed EV-I 20 k-ppt and EV-II 100 k-ppt, were prepared by a combination of size-exclusion chromatography of improved condition and sequential centrifugation...
2024: Frontiers in Molecular Biosciences
keyword
keyword
35658
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.